Difference between revisions of "Essential thrombocythemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "<span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase III</span>" to "style="background-color:#00CD00"|Phase III")
m (Text replacement - "<span style="background:#EEEE00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase II</span>" to "style="background-color:#EEEE00"|Phase II")
Line 153: Line 153:
 
|-
 
|-
 
|[http://jco.ascopubs.org/content/27/32/5418.long Quintás-Cardama et al. 2009]
 
|[http://jco.ascopubs.org/content/27/32/5418.long Quintás-Cardama et al. 2009]
−
|<span
+
|style="background-color:#EEEE00"|Phase II
−
style="background:#EEEE00;
 
−
padding:3px 6px 3px 6px;
 
−
border-color:black;
 
−
border-width:2px;
 
−
border-style:solid;">Phase II</span>
 
 
|-
 
|-
 
|}
 
|}

Revision as of 07:25, 25 October 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

8 regimens on this page
9 variants on this page


Untreated

Aspirin & Anagrelide

back to top

Regimen #1

Study Evidence Comparator
Harrison et al. 2005 (MRC PT-1) Phase III Aspirin & Hydroxyurea

Therapy

  • Anagrelide (Agrylin) 0.5 mg PO twice per day ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
  • Aspirin 75 mg (100 mg in Australia) PO once per day

Regimen #2

Study Evidence Comparator
Gisslinger et al. 2013 (ANAHYDRET) Phase III Hydroxyurea +/- Aspirin

Therapy

  • Anagrelide (Agrylin) 0.5 mg PO twice per day ("increased until maintenance of the platelet count at normal (<=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed content property of HemOnc.org
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains verified protocol PubMed

Aspirin & Hydroxyurea

back to top

Regimen #1

Study Evidence Comparator
Harrison et al. 2005 (MRC PT-1) Phase III Aspirin & Anagrelide

Chemotherapy

  • Hydroxyurea (Hydrea) 500-1000 mg PO once per day ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
  • Aspirin 75 mg (100 mg in Australia) PO once per day

Regimen #2

Study Evidence Comparator
Gisslinger et al. 2013 (ANAHYDRET) Phase III Anagrelide +/- Aspirin

Chemotherapy

  • Hydroxyurea (Hydrea) 1500 mg PO once per day ("increased until maintenance of the platelet count at normal (<=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains verified protocol PubMed

Hydroxyurea (Hydrea)

back to top

Regimen

Study Evidence Comparator
Cortelazzo et al. 1995 Phase III Observation

Chemotherapy

  • Hydroxyurea (Hydrea) 15 mg/kg/day PO
    • Doses were subsequently adjusted to maintain the platelet count at less than 600,000 per cubic millimeter without lowering the white-cell count below 4000 per cubic millimeter

References

  1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed

Observation

back to top

Regimen

Study Evidence Comparator
Cortelazzo et al. 1995 Phase III Hydroxyurea

No active antineoplastic treatment; used as a comparator arm.

References

  1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed

Peginterferon alfa-2a (Pegasys)

back to top

Regimen

Study Evidence
Quintás-Cardama et al. 2009 Phase II

Quintás-Cardama et al. 2009 do not provide guidance on dose escalation or target dosing.

Immunotherapy

Unspecified duration

References

  1. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10;27(32):5418-24. Epub 2009 Oct 13. link to original article contains protocol PubMed
    1. Update: Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Aug 8;122(6):893-901. Epub 2013 Jun 19. link to original article PubMed

Relapsed/Refractory

Peginterferon alfa-2a (Pegasys)

back to top

Regimen

Study Evidence
Verger et al. 2015 Observational

Verger et al. 2015 do not specify a protocol but rather point to the European LeukemiaNet guidelines from 2011. All patients in this study had CALR mutations.

Immunotherapy

References

  1. Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585-91. Epub 2015 Oct 20. link to original article does not contain protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Essential_thrombocythemia&oldid=12351"